eleph room growth
w/ oce broader tech solut portfolio expand
recent massiv roch win well backbon underli
growth acceler given elev book win
manag even foreshadow hope return growth
cso segment anoth challeng period respect
got detail outsid potenti fx headwind
mind accur captur consensu estim
thu expect move modestli lower still point
forward indic skew posit notabl next-gen win
continu grow sequenti all-in continu offer highli
visibl doubl digit compound improv core growth
profil potenti emerg structur winner
evolv cro landscap one slight neg forese
leverag profil remain elev howev would
note much b/ fix natur current effect rate
manag term forecast ep remain
gener constant despit increment fx headwind
move lower fx conserv outlook
leverag rate pt move forward consist
current multipl impli upsid current level
ttm set strong
growth next month
mm award nextgen servic
bring ytd nextgen book bn
ebp book grew bring ytd
roch oce deal bigger eleph clinic deal
fx expect mm hw top-line
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
see top-lin acceler strong ttm book
due increas trial complex downward pressur
contract sale medic solut continu hw
tighten revenu mm vs
fx hw rest year
rais ebitda vs prior
maintain tax rate
rais ep vs prior
remain share repurchas author
earli guid howev indic currenc hw
anticip
record net new biz w/ book growth
pass through cost sever
 growth flattish
see benefit merger top-line end
technolog analyt solut ta use
salesforc new custom engag platform
work w/ salesforc develop
orchestr clinic trial
make clinic trial effici add
success w/ oce sinc decemb
competit space
recent select roch
global deploy
similar
convers larg
continu invest ai technolog suit
invest pull margin
former client spend type
product offer larg opportun
contract sale medic solut csm use
organ
look divest piec decid
go retain turn around
target better perform focus
cost cut bring market
recent enter larg oce contract w/ larg pharma
year contract type biz sticki
larger eleph trial seen quintil
great market opportun oce
w/ larg pharma renew
market larg domin compani
share
origin target new client
larg pharma client work
almost next gen award win
contract
fix price new biz award
top pharma client w/ ms
trial base patient densiti data predict analyt well
anoth top pharma client sever
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin octob
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
